Cancer Metastasis - Biology and Treatment – serie

This book covers the molecular and cellular aspects of cancer metastasis, and discusses the clinical aspect of micro- and macro-metastases, which result in the death of the majority of patients with cancer. This edition attempts to examine the status of the basic scientific and clinical research in the area, and should be a useful reference for clinicians, oncologists, and biologists. It is intended for undergraduates as well as postgraduates in the area of medicine, oncology, and cancer biology.

This text provides knowledge of growth factors and their receptors in cancer metastasis. It covers basic cellular and molecular biology of growth factors and their receptors, as well as their role in cancer and cancer metastasis in clinical settings. The book is intended for cancer biologists, cell biologists, geneticists, oncologists, surgeons and physicians. It is also a reference for those who work in the area of cancer research, cancer therapies, cancer care, the pharmaceutical industry, as well as postgraduates and undergraduates.

This volume provides a summary of the current knowledge about the underlying molecular and biochemical mechanisms controlling the metastatic phenotype. The contents of the volume could be of use to members of the cancer research community and clinicians interested in developing and implementing novel forms of treatment for cancer.

In recent years, serine proteases and matrix metalloproteinases (MMPs) have gained considerable attention in tumour biology. For most of these proteases, their expression is a reliable indication of ongoing tissue remodelling. This book provides a comprehensive evaluation of the mechanisms of action of proteases and their inhibitors in tumour biology. The first part provides the reader with a selective overview of the molecular biology of serine proteases, MMPs and their physiological inhibitors. The most important proteases and their physiological as well as synthetic inhibitors are evaluated in the most relevant models of experimental and human cancer. The clinical aspects are also taken into account. This volume offers an update on this challenging aspect of cancer treatment, its interest bias and possible clinical implication.

Patients with advanced breast or prostate cancers usually develop bone metastases. The principal complications resulting from metastatic bone disease are pain, spinal cord compression, pathologic fractures and bone marrow suppression. Improving the management of bone metastases is crucial to quality of life for patients with breast and prostate cancer. Advances in understanding of the molecular mechanisms underlying the pathophysiology of bone metastasis are driving the development of new therapeutic strategies. The book provides an overview of molecular factors that offer targets and avenues for therapeutic strategies.

Most of the cancer patients die because the tumoral cells do not "stick" in the original site, but instead detach, invade and disseminate throughout the bloodstream to distal sites, where these transformed cells start to proliferate and destroy again. In the last ten years, researchers have identified a number of important genes involved in these processes, including cadherins, laminins, heparan sulfates, inhibitors of proteases and angiogenesis and many others. The puzzling problem was that few genetic alterations in these genes had been described in human tumors, despite the common finding of down-regulation. CpG island hypermethylation-associated silencing has come to the rescue of several of these genes and has situated them in the forefront of the current cancer research. However epigenetic silencing is also much more than aberrant DNA methylation, a whole set of histone modifiers and chromatin remodelling factors "conspire" to maintain the repression of these tumor/metastasis suppressor genes. DNA demethylating agents and inhibitors of histone deacetylases are the first generation of epigenetic drugs to beat them.In this book, the current directions in the epigenetics of cancer progression and metastasis are comprehensively described. It is now the turn of the reader to take care of the future. Dr Manel Esteller, Director, Cancer Epigenetics Laboratory, Spanish National Cancer Centre (CNIO) mesteller@cnio.

Cancer Morbidity and mortality result from invasive and metastatic spread. Currently, no therapies are aimed at the underlying mechanisms that enable this progression due to only nascent recognition of the distinct biology which occurs only during tumor dissemination. Recent advances have highlighted the central role of cell motility during the dynamic and transient process of tumor invasion and metastasis. This book includes state-of-the-art updates by international leaders in these studies. Chapters first present the novel model systems that enable new investigations and insights. Chapters then describe in depth the key processes and molecules that may be therapeutically targeted. Finally, the role of cell motility and its signals is explored in a number of key tumor types. This compilation should be useful to researchers in basic and translational oncology as well as those developing novel agents to prevent tumor invasion and metastasis.

In this volume, the expression of specific adhesion molecules within human cancer tissues are highlighted. The expression signatures from published DNA microarray and immunohistochemistry studies are detailed. The concept that the alteration of specific adhesion molecules influence the cancer migration ability and cancer damage responses is detailed in this volume; both features are essential for the survival of an invading tumor cell. Defining the minimal adhesion receptors preserved on cancer cells during tumor progression will define the metastatic adhesion signature. Understanding the metastatic adhesion signature will reveal vulnerabilities that could be exploited for the prevention and/or eradication of the invading cancer cell.

Without metastasis, prostate cancer would be both tolerable and treatable. The high incidence of indolent and organ confined disease is testament to this sweeping generalisation. Equally, if molecular markers of metastatic spread can be identified, then the choice of treatment for many patients would be easier and more radical, even curative. However, should prevention and treatment of the primary tumors prove difficult or impossible, then a knowledge of the phenotype of advanced metastatic tumors should allow us to target these lesions for destruction by conventional (drug based) or more innovative means such as gene and/or immunotherapy (1). The process of metastasis has been reviewed many times (e. g. , 2) and has been subdivided for ease of analysis into a number of discrete stages (see Figure 1). It has been suggested that at least 10 separate genetic 2. ECM degradation: migration MMP ; Integrin ; TIMP 3. Intravasation MMP TIMP 1. Cellular independence 4. Transport Adhesion loss and evasion (E Cadherin ) of host immune system MHCClass1 ICAM-1 to block T cell receptor 5. Arrest of movement: endothelial adhesion CD44 or switch 6. Extravasation to colonise new site 7. Proliferation at Laminin R distant site to form Integrin switch METASTASIS Figure 1. Stages in prostate cancer metastasis. Basic processes in tumor metastases are indicated in the boxes with some key changes in gene expression indicated at each stage by the solid arrows.

Metastasis (spread of cancer in the body) is the main cause of death for patients with breast cancer, the leading female tumour in the industrialised countries and developing countries alike. The biology and treatment of breast cancer metastasis remains an active area of scientific and clinical investigation.Written by experts in the subject area, the book has covered a broad range of topics in the metastasis of breast cancer, from genetics, biology to clinical management. Main topics include genetic control, biology, growth factors, cell adhesion, cell motility and invasion, natures of bone metastasis, sentinel node therapies, hormonal links, new biomarkers and detection of micrometastasis, and diagnosis The book also covers the current treatment options including surgical management, chemotherapy and hormonal therapies. This timely book provides the current knowledge in the area of breast cancer metastasis and will be of important reading material for oncologists, radiologists, cancer researchers, biologists and health worker.

Bone Metastases: A Translational and Clinical Approach serves as both an introductory and reference book focusing on the field of metastatic bone disease. Featuring contributions from experts in the field, this volume: describes the molecular and cellular mechanisms involved in the formation of bone metastases, comments on the role of angiogenesis, presents the newer advances made in the understanding of the clinical picture and symptoms of patients, analyses the role of bone markers in research and clinical practice deals with all aspects of imaging modalities applied for the detection and evaluation of bone metastases. This volume also covers the use of radiotherapy, surgery and systemic treatments for the management of metastatic bone disease and new therapeutic approaches. Moreover it may also serve as a guide for the clinical and therapeutic management of patients with metastatic bone disease.Overall this volume presents a thorough overview of all aspects of metastatic bone disease and provides a comprehensive and concise information resource for medical researchers, oncologists, orthopaedic surgeons and clinicians.

Metastasis is the primary cause of mortality associated with cancer, and tumor genomic heterogeneity is a likely source for the cells that support cancer progression, resistance to therapy, and disease relapse. This book connects cancer metastasis with genomic instability in a comprehensive manner. Section 1 outlines the fundamental mechanisms responsible for these cellular and tissue phenotypes. Section 2 discusses in silico, in vitro, and in vivo models used for the experimental study of these processes. Section 3 reviews emerging themes (ex., microenvironment, mechanotransduction, and immunomodulation), and Section 4 highlights new therapeutic approaches to overcome the unique challenges presented by the heterogeneous and metastatic tumor. This book is intended for undergraduates and postgraduates with an interest in the areas of medicine, oncology, and cancer biology as well as for the content expert searching for thorough reviews of current knowledge in these areas.

Metastasis is the primary cause of mortality associated with cancer, and tumor genomic heterogeneity is a likely source for the cells that support cancer progression, resistance to therapy, and disease relapse. This book connects cancer metastasis with genomic instability in a comprehensive manner. Section 1 outlines the fundamental mechanisms responsible for these cellular and tissue phenotypes. Section 2 discusses in silico, in vitro, and in vivo models used for the experimental study of these processes. Section 3 reviews emerging themes (ex., microenvironment, mechanotransduction, and immunomodulation), and Section 4 highlights new therapeutic approaches to overcome the unique challenges presented by the heterogeneous and metastatic tumor. This book is intended for undergraduates and postgraduates with an interest in the areas of medicine, oncology, and cancer biology as well as for the content expert searching for thorough reviews of current knowledge in these areas.

Lymphangiogenesis and Cancer Metastasis introduces the new field of lymphatic vessel growth and development, and its relationship to the metastatic spread of cancer cells.The book covers all aspects of this new field from the fundamental role that protein growth factors and their receptors play in lymphangiogenesis to the potential application of these advances to cancer diagnosis and treatment. Other clinical aspects explored include the mechanisms and importance of lymph node metastasis, the role of the lymphatics in lymphangioleiomyomatosis and Kaposi’s sarcoma, and approaches for imaging lymphatics in cancer.The book also covers the innovative approaches taken by researchers to explore new roles for lymphatic vessel biology in the context of cancer. The information presented in this volume, which describes the revolutionary concepts of tumor lymphangiogenesis, will be of interest to all students, scientists and oncologists who are seeking to understand the complexities of tumor metastasis.Key Features:Presents fundamental concepts of tumor lymphangiogenesis and the molecules which control this processProvides a comprehensive summary of current research in this ground breaking areaProvides a book which links progress in basic tumor and developmental biology with current and future oncology practiseIs an essential text for molecular biologists, cell biologists and oncologists seeking to understand the implications of this rapidly developing area.

Written by experts worldwide, this book provides the current knowledge of growth factors and their receptors in cancer metastasis. It covers basic cellular and molecular biology of growth factors and their receptors, as well as their role in cancer and cancer metastasis in clinical settings. The book is intended for cancer biologists, cell biologists, biochemists, geneticists, oncologists, surgeons and physicians. It is also a valuable reference for those who work in the area of cancer research, cancer therapies, cancer care, pharmaceutical industry. Postgraduates and undergraduates who pursue a research career in cancer and growth factors will find it an extremely useful reference book.

In recent years, serine proteases and matrix metalloproteinases (MMPs) have gained considerable attention in tumor biology. For most of these proteases, their expression is a reliable indication of ongoing tissue remodeling. This book provides a comprehensive evaluation of the mechanisms of action of proteases and their inhibitors in tumor biology. The first part provides the reader with a selective overview of the molecular biology of serine proteases, MMPs and their physiological inhibitors. The most important proteases and their physiological as well as synthetic inhibitors are evaluated in the most relevant models of experimental and human cancer. The clinical aspects are also taken into account. This volume offers an update on this challenging aspect of cancer treatment, its interest bias, and possible clinical implication.

Patients with advanced breast or prostate cancers usually develop bone metastases. The principal complications resulting from metastatic bone disease are pain, spinal cord compression, pathologic fractures and bone marrow suppression. Improving the management of bone metastases is crucial to quality of life for patients with breast and prostate cancer. Advances in understanding of the molecular mechanisms underlying the pathophysiology of bone metastasis are driving the development of new therapeutic strategies.

Most of the cancer patients die because the tumoral cells do not "stick" in the original site, but instead detach, invade and disseminate throughout the bloodstream to distal sites, where these transformed cells start to proliferate and destroy again. In the last ten years, researchers have identified a number of important genes involved in these processes, including cadherins, laminins, heparan sulfates, inhibitors of proteases and angiogenesis and many others. The puzzling problem was that few genetic alterations in these genes had been described in human tumors, despite the common finding of down-regulation. CpG island hypermethylation-associated silencing has come to the rescue of several of these genes and has situated them in the forefront of the current cancer research. However epigenetic silencing is also much more than aberrant DNA methylation, a whole set of histone modifiers and chromatin remodelling factors "conspire" to maintain the repression of these tumor/metastasis suppressor genes. DNA demethylating agents and inhibitors of histone deacetylases are the first generation of epigenetic drugs to beat them.In this book, the current directions in the epigenetics of cancer progression and metastasis are comprehensively described. It is now the turn of the reader to take care of the future. Dr Manel Esteller, Director, Cancer Epigenetics Laboratory, Spanish National Cancer Centre (CNIO) mesteller@cnio.

Cancer Morbidity and mortality result from invasive and metastatic spread. Currently, no therapies are aimed at the underlying mechanisms that enable this progression due to only nascent recognition of the distinct biology which occurs only during tumor dissemination. Recent advances have highlighted the central role of cell motility during the dynamic and transient process of tumor invasion and metastasis. This book includes state-of-the-art updates by international leaders in these studies. Chapters first present the novel model systems that enable new investigations and insights. Chapters then describe in depth the key processes and molecules that may be therapeutically targeted. Finally, the role of cell motility and its signals is explored in a number of key tumor types. This compilation should be useful to researchers in basic and translational oncology as well as those developing novel agents to prevent tumor invasion and metastasis.

In this volume, the expression of specific adhesion molecules within human cancer tissues are highlighted. The expression signatures from published DNA microarray and immunohistochemistry studies are detailed. The concept that the alteration of specific adhesion molecules influence the cancer migration ability and cancer damage responses is detailed in this volume; both features are essential for the survival of an invading tumor cell. Defining the minimal adhesion receptors preserved on cancer cells during tumor progression will define the metastatic adhesion signature. Understanding the metastatic adhesion signature will reveal vulnerabilities that could be exploited for the prevention and/or eradication of the invading cancer cell.

Colorectal cancer is the third most common cancer worldwide, and in many parts of the western world, it is the second leading cause of cancer-related deaths. This book covers colon cancer metastasis from the most fundamental aspects to clinical practice. Major topics include physiopathology, genetic and epigenetic controls, cancer initiating cells, epithelial-mesenchymal transition, growth factors and signalling, cell adhesion, natures of liver metastasis, angiogenesis and lymphangiogenesis, inflammatory response, prognostic markers, sentinel node and staging, and finally diagnosis and treatment. Each chapter has been contributed by leaders in the field. A key feature is that it connects with a large readership including students, fundamentalists and clinicians. Another specific feature of the book is that the chapters are written in a didactic and illustrative fashion. These characteristics coupled with the choice of the topics and authors, makes this book a reference in the field. It represents an essential acquisition for medical libraries, clinicians as well as medical and graduate students.

Cancerremainstobeoneofthemostdevastatingdiseasesworldwidesincelong ago. Thepoorprognosisofcancerislargelyduetometastasis. Metastasisisoften depictedasamultistageprocessinwhichmalignantcellsspreadfromtheprimary locustodistantorgansviacirculation. Whereasgeneticalterationsweresuggested tobeessentialfortransformationofprimarytumorcellsintometastaticphenotype, epigeneticeventsareequallyimportant,whichmaybetriggeredbymetastaticf- torswhereverintheprimarytumorlocus,bloodcirculationandthesecondaryloci. Signaltransductionsinitiatedbythemetastaticfactorsareresponsibleformediating themolecularandcellularprocessesleadingtometastasis. Blockadeoftherelevant molecularpathwaysisoneofthemosteffectivestrategiesforpreventionoftumor metastasis. Clinicaltrialsareunderwaywithpromisingoutcome. Inthisbook, wetakecomprehensive review inregard withthisexciting eld ofcancerresearch. Chapter1takesabriefoverviewofrecentlyidenti edsignal mechanismsforeachstepoftumormetastasisincludingtheinitiationstage,intra- sation,anti-anoikisinbloodcirculation,homing,extravasationand nalsurvivalin themetastaticsite. Chapter2makesacompletedreviewforthemolecularandcel- lareventsinvolvedininitiationofmetastasis.Especially,thesignalingmechanisms formediatingtumorprogressioninducedbysomeimportantmetastaticfactorsare described. InChapters3and4,thecentralrolesofMAPKanditsdownstreameff- torsMAPKAPKplayineachstepoftumormetastasisarewelldelineated. Chapter5 furtherdescribesdetailedlyabouthowGrb2andotheradaptorproteins,upstreamof MAPK cascade, contribute tometastasis. InChapter 6, therole ofreactive o- genspecies(ROS)intumorprogressionarehighlighted. Moreover,thepotential contribution of ROS to cross talk between major signaling cascades that lead to sustainedMAPKactivationareproposedinChapter7. Chapter8takesaninsight intothesignalingmechanismsfordynamictraf ckingandturnoveroffocalad- sionproteinsinregulationoftractionandretractionforces,whichareneededfor celllocomotionandinvasion. Chapter9describestheinvolvementofNotchsign- ingpathwaywhichisnotonlyessentialforembryonicdevelopmentbutalsoplays importantroleintumorprogression. Chapter10reviewedtherecentlyidenti ed cancer- and metastasis-initiating cells involved in tumor progression. Especially, signal pathways that are frequently deregulated in cancer stem/progenitor cells v vi Preface duringcancerprogressionarehighlighted.Chapter11describestheroleoflipid rafts, a special component within membrane lipid domain, in signal transd- tion triggered by growth factor receptors leading to tumor metastasis. Finally, Chapters12,Chapters13,andChapters14presentthesignalingpathwaysresp- sibleformetastaticprogressionofspeci ctumorsincludingovariancancer,uveal melanomaandhepatoma,respectively. WethankallthecontributorsofeveryChapterinthebookincludingJia-RuWu, Chi-TanHu,LaureVoisin,StephanieDuhamel,SylvainMeloche,AlexeyShiryaev, MarijkeVanGhelue,UgoMoens,AlessioGiubellino,PraveenR. Arany,Moulay A. Alaoui-Jamali, Krikor Bijian, Panagiota Toliopoulos, Pingyu Zhang, Patrick A. Zweidler-McKay,MurielleMimeault,SurinderK. Batra,SamirKumarPatra, LydiaW. T. Cheung,CarmanK. M. Ip,AliceS. T. Wong,CecileLaurent,Jerome Couturier,XavierSastre-Garau,LaurenceDesjardins,EmmanuelBarillot,Sophie Piperno-Neumann,SimonSauleandRajagopalN. Aravalli. Wehopethisbookmightstimulatemorecancerbiologiststoemphasizethis eld whichbene tsdevisingmoreeffectivemoleculartargetingstrategiesforprevention ofcancermetastasis. Hualien,Taiwan Wen-ShengWu Chi-TanHu Contents 1 Overview of Signal Transduction in Tumor Metastasis...1Wen-ShengWuandJia-RuWu 2 Microenvironment Triggers EMT, Migration and Invasion of Primary Tumor via Multiple Signal Pathways ...9 Wen-ShengWuandChi-TanHu 3 The ERK1/2 MAP Kinase Signaling Pathway in Tumor Progression and Metastasis ...25 LaureVoisin,StephanieDuhamel,andSylvainMeloche 4 Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis...41 AlexeyShiryaev,MarijkeVanGhelue,andUgoMoens 5 Grb2 and Other Adaptor Proteins in Tumor Metastasis ...77 AlessioGiubellinoandPraveenR. Arany 6 The Role of ROS Signaling in Tumor Progression...103 Wen-ShengWuandJia-RuWu 7 Signal Cross Talks for Sustained MAPK Activation and Cell Migration Mediated by Reactive Oxygen Species: The Involvement in Tumor Progression...

Liver metastases are a frequent and often fatal occurrence in cancer patients, particularly those with malignancies of the gastrointestinal (GI) tract. While recent improvements in surgical techniques and a more aggressive approach to resection of liver metastases have improved long term survival for some patients, most patients with hepatic metastases still succumb to their disease. To improve these dismal statistics, a better understanding of the biology of liver metastasis, particularly the early stages that can be targeted for prevention, is essential.   Once cancer cells enter the liver, several different scenarios may occur. The cancer cells may be immediately destroyed by local defence mechanisms, they may enter a state of dormancy as solitary cells and never produce a metastasis, initiate a short-lived process of proliferation that is aborted before a metastasis is established or actively proliferate to form macrometastases. The chapters in Part I of this book provide insight into the cellular/molecular mechanisms that determine which of these scenarios prevails.   Written by experts researchers in the filed of metastasis, these chapters provide state-of-the art reviews on the cellular and molecular processes that impact the early stages of the metastatic process. The unique microenvironment of the liver, its various anatomical, cellular and molecular features and the impact they have on metastasis are highlighted. In addition, the role of inflammation (pre-existing and tumor-induced), host innate and adaptive immune responses, cytokines, chemokines, growth factors and the unique molecular signatures of metastatic tumor cells are reviewed with an underscoring of thetranslational implications of the current state of knowledge.   Against this background, the chapters in Part II of the book provide critical reviews on major aspects of the clinical management of hepatic metastases. These include imaging strategies, surgical and chemotherapeutic treatment approaches and the use of targeted biological therapeutics such as anti-angiogenic drugs as treatment modalities. By combining information on biological and clinical aspects of liver metastasis, this volume  will serve as an excellent resource for scientists, clinicians, clinician/ scientists and trainees in the domains of oncology, surgical oncology, hepatobiliary physiology and radiology.

Lymphangiogenesis and Cancer Metastasis introduces the new field of lymphatic vessel growth and development, and its relationship to the metastatic spread of cancer cells.The book covers all aspects of this new field from the fundamental role that protein growth factors and their receptors play in lymphangiogenesis to the potential application of these advances to cancer diagnosis and treatment. Other clinical aspects explored include the mechanisms and importance of lymph node metastasis, the role of the lymphatics in lymphangioleiomyomatosis and Kaposi’s sarcoma, and approaches for imaging lymphatics in cancer.The book also covers the innovative approaches taken by researchers to explore new roles for lymphatic vessel biology in the context of cancer. The information presented in this volume, which describes the revolutionary concepts of tumor lymphangiogenesis, will be of interest to all students, scientists and oncologists who are seeking to understand the complexities of tumor metastasis.Key Features:Presents fundamental concepts of tumor lymphangiogenesis and the molecules which control this processProvides a comprehensive summary of current research in this ground breaking areaProvides a book which links progress in basic tumor and developmental biology with current and future oncology practiseIs an essential text for molecular biologists, cell biologists and oncologists seeking to understand the implications of this rapidly developing area.

Colorectal cancer is the third most common cancer worldwide, and in many parts of the western world, it is the second leading cause of cancer-related deaths. This book covers colon cancer metastasis from the most fundamental aspects to clinical practice. Major topics include physiopathology, genetic and epigenetic controls, cancer initiating cells, epithelial-mesenchymal transition, growth factors and signalling, cell adhesion, natures of liver metastasis, angiogenesis and lymphangiogenesis, inflammatory response, prognostic markers, sentinel node and staging, and finally diagnosis and treatment. Each chapter has been contributed by leaders in the field. A key feature is that it connects with a large readership including students, fundamentalists and clinicians. Another specific feature of the book is that the chapters are written in a didactic and illustrative fashion. These characteristics coupled with the choice of the topics and authors, makes this book a reference in the field. It represents an essential acquisition for medical libraries, clinicians as well as medical and graduate students.

Cancerremainstobeoneofthemostdevastatingdiseasesworldwidesincelong ago. Thepoorprognosisofcancerislargelyduetometastasis. Metastasisisoften depictedasamultistageprocessinwhichmalignantcellsspreadfromtheprimary locustodistantorgansviacirculation. Whereasgeneticalterationsweresuggested tobeessentialfortransformationofprimarytumorcellsintometastaticphenotype, epigeneticeventsareequallyimportant,whichmaybetriggeredbymetastaticf- torswhereverintheprimarytumorlocus,bloodcirculationandthesecondaryloci. Signaltransductionsinitiatedbythemetastaticfactorsareresponsibleformediating themolecularandcellularprocessesleadingtometastasis. Blockadeoftherelevant molecularpathwaysisoneofthemosteffectivestrategiesforpreventionoftumor metastasis. Clinicaltrialsareunderwaywithpromisingoutcome. Inthisbook, wetakecomprehensive review inregard withthisexciting eld ofcancerresearch. Chapter1takesabriefoverviewofrecentlyidenti edsignal mechanismsforeachstepoftumormetastasisincludingtheinitiationstage,intra- sation,anti-anoikisinbloodcirculation,homing,extravasationand nalsurvivalin themetastaticsite. Chapter2makesacompletedreviewforthemolecularandcel- lareventsinvolvedininitiationofmetastasis.Especially,thesignalingmechanisms formediatingtumorprogressioninducedbysomeimportantmetastaticfactorsare described. InChapters3and4,thecentralrolesofMAPKanditsdownstreameff- torsMAPKAPKplayineachstepoftumormetastasisarewelldelineated. Chapter5 furtherdescribesdetailedlyabouthowGrb2andotheradaptorproteins,upstreamof MAPK cascade, contribute tometastasis. InChapter 6, therole ofreactive o- genspecies(ROS)intumorprogressionarehighlighted. Moreover,thepotential contribution of ROS to cross talk between major signaling cascades that lead to sustainedMAPKactivationareproposedinChapter7. Chapter8takesaninsight intothesignalingmechanismsfordynamictraf ckingandturnoveroffocalad- sionproteinsinregulationoftractionandretractionforces,whichareneededfor celllocomotionandinvasion. Chapter9describestheinvolvementofNotchsign- ingpathwaywhichisnotonlyessentialforembryonicdevelopmentbutalsoplays importantroleintumorprogression. Chapter10reviewedtherecentlyidenti ed cancer- and metastasis-initiating cells involved in tumor progression. Especially, signal pathways that are frequently deregulated in cancer stem/progenitor cells v vi Preface duringcancerprogressionarehighlighted.Chapter11describestheroleoflipid rafts, a special component within membrane lipid domain, in signal transd- tion triggered by growth factor receptors leading to tumor metastasis. Finally, Chapters12,Chapters13,andChapters14presentthesignalingpathwaysresp- sibleformetastaticprogressionofspeci ctumorsincludingovariancancer,uveal melanomaandhepatoma,respectively. WethankallthecontributorsofeveryChapterinthebookincludingJia-RuWu, Chi-TanHu,LaureVoisin,StephanieDuhamel,SylvainMeloche,AlexeyShiryaev, MarijkeVanGhelue,UgoMoens,AlessioGiubellino,PraveenR. Arany,Moulay A. Alaoui-Jamali, Krikor Bijian, Panagiota Toliopoulos, Pingyu Zhang, Patrick A. Zweidler-McKay,MurielleMimeault,SurinderK. Batra,SamirKumarPatra, LydiaW. T. Cheung,CarmanK. M. Ip,AliceS. T. Wong,CecileLaurent,Jerome Couturier,XavierSastre-Garau,LaurenceDesjardins,EmmanuelBarillot,Sophie Piperno-Neumann,SimonSauleandRajagopalN. Aravalli. Wehopethisbookmightstimulatemorecancerbiologiststoemphasizethis eld whichbene tsdevisingmoreeffectivemoleculartargetingstrategiesforprevention ofcancermetastasis. Hualien,Taiwan Wen-ShengWu Chi-TanHu Contents 1 Overview of Signal Transduction in Tumor Metastasis...1Wen-ShengWuandJia-RuWu 2 Microenvironment Triggers EMT, Migration and Invasion of Primary Tumor via Multiple Signal Pathways ...9 Wen-ShengWuandChi-TanHu 3 The ERK1/2 MAP Kinase Signaling Pathway in Tumor Progression and Metastasis ...25 LaureVoisin,StephanieDuhamel,andSylvainMeloche 4 Mitogen-Activated Protein Kinase-Activated Protein Kinases and Metastasis...41 AlexeyShiryaev,MarijkeVanGhelue,andUgoMoens 5 Grb2 and Other Adaptor Proteins in Tumor Metastasis ...77 AlessioGiubellinoandPraveenR. Arany 6 The Role of ROS Signaling in Tumor Progression...103 Wen-ShengWuandJia-RuWu 7 Signal Cross Talks for Sustained MAPK Activation and Cell Migration Mediated by Reactive Oxygen Species: The Involvement in Tumor Progression...

Liver metastases are a frequent and often fatal occurrence in cancer patients, particularly those with malignancies of the gastrointestinal (GI) tract. While recent improvements in surgical techniques and a more aggressive approach to resection of liver metastases have improved long term survival for some patients, most patients with hepatic metastases still succumb to their disease. To improve these dismal statistics, a better understanding of the biology of liver metastasis, particularly the early stages that can be targeted for prevention, is essential.   Once cancer cells enter the liver, several different scenarios may occur. The cancer cells may be immediately destroyed by local defence mechanisms, they may enter a state of dormancy as solitary cells and never produce a metastasis, initiate a short-lived process of proliferation that is aborted before a metastasis is established or actively proliferate to form macrometastases. The chapters in Part I of this book provide insight into the cellular/molecular mechanisms that determine which of these scenarios prevails.   Written by experts researchers in the filed of metastasis, these chapters provide state-of-the art reviews on the cellular and molecular processes that impact the early stages of the metastatic process. The unique microenvironment of the liver, its various anatomical, cellular and molecular features and the impact they have on metastasis are highlighted. In addition, the role of inflammation (pre-existing and tumor-induced), host innate and adaptive immune responses, cytokines, chemokines, growth factors and the unique molecular signatures of metastatic tumor cells are reviewed with an underscoring of thetranslational implications of the current state of knowledge.   Against this background, the chapters in Part II of the book provide critical reviews on major aspects of the clinical management of hepatic metastases. These include imaging strategies, surgical and chemotherapeutic treatment approaches and the use of targeted biological therapeutics such as anti-angiogenic drugs as treatment modalities. By combining information on biological and clinical aspects of liver metastasis, this volume  will serve as an excellent resource for scientists, clinicians, clinician/ scientists and trainees in the domains of oncology, surgical oncology, hepatobiliary physiology and radiology.

Cell based impedance sensing is becoming a new biophysical and cellular technology in cell based analyses. The technology has been used in investigation of cellular growth and death, cell adhesion and migration, cell invasion and cell-cell interactions, cell toxicity, angiogenesis, cell permeability, signal transduction and cellular behaviour under flow conditions. It is a probe free, highly sensitive, and versatile technology platform. Recent development in the technology has also allowed high throughput, automated analyses. It has been widely explored in chemistry, toxicity, cell biology, cancer biology, and other areas of chemistry, medicinal chemistry, life and medical science. Written by experts in the area of cell impedance sensing, including the Nobel Laureate Dr Ivar Giaever, this books covers the background of electric cell-substrate impedance sensing, their applications in cell based investigations, particularly in the area of cancer biology. This book is the first on thistechnology platform and will be a highly useful reference for molecular and cell biologists, cancer biologists, chemists and biochemists, clinical researchers who work in the areas of cell biology, molecular biology, toxicology, pharmaceutical industry, life science and medical research.

This volume will cover what is known regarding the biology and treatment of CNS metastasis, including novel chapters such as the future of targeted therapies.  It will begin with an overview of the natural history and risk factors for CNS metastases that will broadly cover all cancer histologies.   This will be followed by 3 chapters that will cover the biology. These include: molecular biology, discussing what is known about specific genes/proteins involved in the process and model systems to study brain metastasis; the brain microenvironment, focusing on how it is different from the microenvironment of other organs of the body; and the blood-brain barrier,  which includes a discussion of permeability with respect to brain metastases.  A chapter on experimental imaging will cover both the biology of brain metastasis from an imaging perspective and use of imaging techniques to study brain metastases.  The clinical chapters will discuss treatment options with separate chapters on surgery, chemotherapy and radiation.  In addition, leptomeningeal metastasis will be given its own chapter.  Finally, quality of life issues will be the concluding chapter.